Trump Administration Accelerates Psychedelic Drug Review for Mental Health Treatments President Trump signs an executive order to fast-track FDA review of breakthrough psychedelic therapies, including ibogaine, aiming to improve access to potentially life-changing treatments for severe mental illness and veterans. President Donald Trump has signed an executive order aimed at accelerating the review process for psychedelic drugs designated as breakthrough therapies by the Food and Drug Administration. This significant move, announced on a Saturday, signals a potential paradigm shift in the treatment of severe mental illness, including depression and conditions affecting veterans. The President emphasized that these experimental treatments are in advanced clinical trials, demonstrating both safety and efficacy for American patients. The executive order is designed to cut through bureaucratic red tape, enhance data sharing between the FDA and the Department of Veterans Affairs, and expedite the rescheduling of any psychedelic drugs that receive FDA approval. Trump highlighted the life-changing potential of these therapies, particularly for those suffering from severe mental health challenges and underscored the concerning rate of veteran suicides as a driving factor behind this initiative. He pointed to a 2024 Stanford University study involving 30 special operations veterans with traumatic brain injuries who underwent ibogaine treatment. Within a month, these veterans reportedly experienced an 80% to 90% reduction in depression and anxiety symptoms. Further bolstering this commitment, Republican leaders in Texas have allocated $50 million towards ibogaine research, and the federal government is now matching this investment with its own $50 million research allocation, approved the previous night. The order also establishes a pathway for desperately ill patients to access ibogaine under the right-to-try law, offering a beacon of hope for individuals to reclaim their lives. A paper published in the journal Chronic Stress describes ibogaine as a psychoactive indole alkaloid derived from the Tabernanthe iboga rainforest shrub, with a history of use in Central African initiatory rituals. The research suggests ibogaine can alleviate a range of mood and anxiety symptoms, and improve cognitive functioning in individuals with substance-use disorders. Importantly, ibogaine treatment is reported to facilitate the evocation and reprocessing of traumatic memories, leading to therapeutic and meaningful visions that are crucial for addressing psychological content related to PTSD. Health and Human Services Secretary Robert F. Kennedy Jr. stated that the order will expedite research approval and access to new mental health treatments, including psychedelic therapies like ibogaine, acknowledging it as a decisive step to confront the nation's urgent mental health crisis. He cited statistics indicating over 14 million Americans live with serious mental illness, with a significant portion experiencing diagnosable disorders annually, and a concerning rise in suicide rates, particularly among veterans, who have lost more lives to suicide than to combat since 2001. The initiative also received a notable endorsement from podcaster Joe Rogan, who was present at the Oval Office. Rogan recounted how conversations on his podcast with Bryan Hubbard and former Texas Gov. Rick Perry about the profound impact of ibogaine inspired him to advocate for its wider recognition and accessibility. He emphasized that these discussions allowed millions to hear about life-changing experiences facilitated by this medicine.